Osaka Medical Center for Cancer and Cardiovascular Diseases
Osaka, Japan
NCT Number: NCT01294085
To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.
Looking for future studies?
Notify Me20 year and older
All sexes
Observational
Osaka, Japan
Most patients of biliary tract cancer have advanced disease at diagnosis and often relapse despite surgery. Combination therapy of gemcitabine and cisplatin could be a standard therapy for this kind of cancer with the evidence of phase III study compared with gemcitabine alone. However the prognosis and the tolerability of chemotherapy in the patients with recurrent biliary tract cancer after radical resection might differ from those of unresectable biliary tract cancer, because the dose intensity of chemotherapy can be influenced by adjuvant chemotherapy and/or hepatic resection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Time frame: 3 years
Time frame: 3 years
Time frame: 3 years
Looking for future studies?
Notify MeKansai Hepatobiliary Oncology Group
Network
Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05835778
Biliary Tract Cancer, Biliary Tract Diseases
Aichi, Japan
View Trial DetailsNCT05297903
Biliary Tract Cancer, Biliary Tract Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07830147
Biliary Tract Cancer, Biliary Tract Diseases
Chengdu, Sichuan, China
View Trial DetailsNCT05220046
Biliary Tract Cancer, Biliary Tract Diseases
Omaha, Nebraska, United States
View Trial Details